These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16980210)

  • 1. Treating very early rheumatoid arthritis.
    Raza K; Buckley CE; Salmon M; Buckley CD
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):849-63. PubMed ID: 16980210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.
    Hwang YG; Moreland LW
    Curr Rheumatol Rep; 2014 May; 16(5):417. PubMed ID: 24619653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study.
    Saleem B; Brown AK; Keen H; Nizam S; Freeston J; Karim Z; Quinn M; Wakefield R; Hensor E; Conaghan PG; Emery P
    Arthritis Rheum; 2009 Jul; 60(7):1915-22. PubMed ID: 19565512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
    van Nies JA; Tsonaka R; Gaujoux-Viala C; Fautrel B; van der Helm-van Mil AH
    Ann Rheum Dis; 2015 May; 74(5):806-12. PubMed ID: 25561360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical synovitis measured by ultrasound in rheumatoid arthritis patients with clinical remission induced by synthetic and biological modifying disease drugs.
    Cruces M; Al Snih S; Serra-Bonett N; Rivas JC
    Reumatol Clin (Engl Ed); 2019; 15(4):218-222. PubMed ID: 29032909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis.
    Forslind K; Svensson B
    Scand J Rheumatol; 2016; 45(2):99-102. PubMed ID: 26313244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor alpha agents.
    Martínez-Martínez MU; Cuevas-Orta E; Reyes-Vaca G; Baranda L; González-Amaro R; Abud-Mendoza C
    Ann Rheum Dis; 2007 Jan; 66(1):134-5. PubMed ID: 17178761
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen.
    Ma MH; Scott IC; Dahanayake C; Cope AP; Scott DL
    J Rheumatol; 2014 Jul; 41(7):1298-303. PubMed ID: 24931951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
    Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis].
    Finckh A; Gabay C; Guerne PA
    Rev Med Suisse Romande; 2004 Sep; 124(9):547-50. PubMed ID: 15552748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.
    Hetland ML; Stengaard-Pedersen K; Junker P; Østergaard M; Ejbjerg BJ; Jacobsen S; Lottenburger T; Hansen I; Tarp U; Andersen LS; Svendsen A; Pedersen JK; Lauridsen UB; Ellingsen T; Lindegaard H; Pødenphant J; Vestergaard A; Jurik AG; Hørslev-Petersen K;
    Ann Rheum Dis; 2010 Oct; 69(10):1789-95. PubMed ID: 20444751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early rheumatoid arthritis].
    Atzeni F; Sarzi-Puttini P
    Reumatismo; 2007; 59(2):100-17. PubMed ID: 17603690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis.
    Jung YO; Kim HA
    Korean J Intern Med; 2012 Dec; 27(4):378-87. PubMed ID: 23269876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF treatment in rheumatoid arthritis.
    Geiler J; Buch M; McDermott MF
    Curr Pharm Des; 2011; 17(29):3141-54. PubMed ID: 21864263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.